A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Table 4 Univariate analyses of biomarker and treatment outcomes

		RR (%)	P-value	Median TTP (mo)	P-value	Median OS (mo)	P-value
Tumor expression (IHC)
pEGFR	negative	32.4	0.79	5.3	0.50	7.8	0.52
pEGFR	positive	28.6		4.3		9.1
pAKT	negative	29.6	0.78	5.2	0.50	8.1	0.39
pAKT	positive	33.3		4.0		9.1
P27	negative	23.1	0.22	4.9	0.25	7.3	0.33
	positive	40.9		5.6		9.2
	positive	34.3		5.1		9.2
PTEN	negative	31.1	0.56	4.4	0.28	8.2	0.39
PTEN	positive	35.2		4.9		9.0
Serum protein level (ELISA) (pg/ml)
VEGF	≤12.6	55.0	0.001	6.9	0.0005	12	<0.0001
VEGF	>12.6	5.3		2.8		5
EGF	≤0.70	31.8	1.00	4.7	0.61	8.3	0.58
EGF	>0.70	29.4		4.0		8.9

RR response rate, TTP time-to-progression, OS overall survival, mo months, IHC immunohistochemistry, PEGFR phosphorylated epidermal growth factor receptor, PAKT phosphorylated AKT, ELISA enzyme-linked immunosorbent assay, VEGF vascular endothelial growth factor, EGF epidermal growth factor, mTOR mammalian target of rapamycin, PTEN phosphatase and tensin homolog deleted on chromosome ten. P < 0.05 are significant and marked in bold

ISSN: 1471-2407